Acorda Therapeutics, Inc.
ACOR · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $3,117 | $2,532 | $4,232 | $5,578 |
| - Cash | $30,360 | $37,536 | $45,634 | $71,369 |
| + Debt | $190,897 | $172,917 | $190,942 | $259,949 |
| Enterprise Value | $163,654 | $137,913 | $149,540 | $194,158 |
| Revenue | $117,633 | $118,566 | $129,071 | $152,967 |
| % Growth | -0.8% | -8.1% | -15.6% | – |
| Gross Profit | $71,586 | $88,234 | $88,284 | $119,454 |
| % Margin | 60.9% | 74.4% | 68.4% | 78.1% |
| EBITDA | -$201,819 | -$10,030 | -$44,796 | -$64,955 |
| % Margin | -171.6% | -8.5% | -34.7% | -42.5% |
| Net Income | -$252,854 | -$65,916 | -$103,954 | -$99,594 |
| % Margin | -215% | -55.6% | -80.5% | -65.1% |
| EPS Diluted | -203.59 | -66.9 | -195.75 | -246.4 |
| % Growth | -204.3% | 65.8% | 20.6% | – |
| Operating Cash Flow | -$13,984 | -$20,924 | -$41,348 | -$61,006 |
| Capital Expenditures | -$264 | -$136 | -$191 | -$4,390 |
| Free Cash Flow | -$14,248 | -$21,060 | -$41,539 | -$65,396 |